Zobrazeno 1 - 10
of 110
pro vyhledávání: '"R. Scott Turner"'
Autor:
Max Stevenson, Rency Varghese, Michaeline L. Hebron, Xiaoguang Liu, Nick Ratliff, Amelia Smith, R. Scott Turner, Charbel Moussa
Publikováno v:
Journal of Neuroinflammation, Vol 20, Iss 1, Pp 1-12 (2023)
Abstract Discoidin Domain Receptor (DDR)-1 is activated by collagen. Nilotinib is a tyrosine kinase inhibitor that is FDA-approved for leukemia and potently inhibits DDR-1. Individuals diagnosed with mild–moderate Alzheimer’s disease (AD) treated
Externí odkaz:
https://doaj.org/article/e25ad3d27a9d4b9aa56025dd33e019df
Publikováno v:
Frontiers in Neuroscience, Vol 17 (2023)
Alzheimer’s Disease (AD) and related dementias are a leading cause of death globally and are predicted to increase in prevalence. Despite this expected increase in the prevalence of AD, we have yet to elucidate the causality of the neurodegeneratio
Externí odkaz:
https://doaj.org/article/9a2610d8cd264448b3ef0eb6619f773b
Autor:
Griffin A. Greco, Mitchell Rock, Matthew Amontree, Maria Fe Lanfranco, Holly Korthas, Sung Hyeok Hong, R. Scott Turner, G. William Rebeck, Katherine Conant
Publikováno v:
Neurobiology of Disease, Vol 179, Iss , Pp 106057- (2023)
The APOE4 allele increases the risk for Alzheimer's disease (AD) in a dose-dependent manner and is also associated with cognitive decline in non-demented elderly controls. In mice with targeted gene replacement (TR) of murine APOE with human APOE3 or
Externí odkaz:
https://doaj.org/article/fd4b70330d404358b61b5d8721a3fd22
Autor:
Charles G. Withington, R. Scott Turner
Publikováno v:
Frontiers in Neurology, Vol 13 (2022)
Second-generation anti-amyloid monoclonal antibodies are emerging as a viable therapeutic option for individuals with prodromal and mild dementia due to Alzheimer's disease (AD). Passive immunotherapy with aducanumab (Aduhelm), lecanemab, donanemab,
Externí odkaz:
https://doaj.org/article/45ba4f90a6594044a58041fa594c97d6
Autor:
Fernando L. Pagan, Yasar Torres‐Yaghi, Michaeline L. Hebron, Barbara Wilmarth, R. Scott Turner, Sara Matar, Dalila Ferrante, Jaeil Ahn, Charbel Moussa
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 8, Iss 1, Pp n/a-n/a (2022)
Abstract Introduction Bosutinib, a dual Abelson/Src inhibitor, was investigated in individuals with dementia with Lewy bodies (DLB). Methods A single site, randomized, double‐blind, placebo‐controlled study of the effects of oral bosutinib, 100 m
Externí odkaz:
https://doaj.org/article/003e9803bd3344659874b1f34a070969
Publikováno v:
Frontiers in Neurology, Vol 11 (2020)
Dementia is an umbrella term—caused by a large number of specific diagnoses, including several neurodegenerative disorders. Alzheimer's disease (AD) is now the most common cause of dementia in advanced countries, while dementia due to neurosyphilis
Externí odkaz:
https://doaj.org/article/3ac41bf30dec4f0ebba0502a21bc0e11
Publikováno v:
Neurobiology of Disease, Vol 36, Iss 1, Pp 162-168 (2009)
The neuronal adaptor protein X11α/mint-1/APBA-1 binds to the cytoplasmic domain of the amyloid precursor protein (APP) to modulate its trafficking and metabolism. We investigated the consequences of reducing X11α in a mouse model of Alzheimer's dis
Externí odkaz:
https://doaj.org/article/21dc208aec184330a3e16312f762bbfb
Publikováno v:
Frontiers in Psychology, Vol 6 (2015)
Anomia treatment efficacy has been examined in cases with different subtypes of primary progressive aphasia (PPA), and it has been evaluated in groups of participants with the semantic variant (svPPA), but efficacy has not been examined in groups wit
Externí odkaz:
https://doaj.org/article/af85f55056554474af96340474d56687
Autor:
Max Stevenson, Rency Varghese, Michaeline Hebron, Xiaoguang Liu, Nick Ratliff, Amelia Smith, R. Scott Turner, Charbel Moussa
Discoidin Domain Receptor (DDR)-1 is activated by collagen. Nilotinib is a tyrosine kinase inhibitor that is FDA-approved for leukemia and potently inhibits DDR-1. Individuals diagnosed with mild-moderate Alzheimer’s disease (AD) treated with nilot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::627320c1abdde0d1ba5ff9195e4a7a74
https://doi.org/10.21203/rs.3.rs-2705486/v1
https://doi.org/10.21203/rs.3.rs-2705486/v1
Publikováno v:
Digital Health, Vol 7 (2021)
Digital Health
Digital Health
ObjectiveThere is a critical need to develop rapid, inexpensive and easily accessible screening tools for mild cognitive impairment (MCI) and Alzheimer’s disease (AD). We report on the efficacy of collecting speech via the telephone to subsequently
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21f2a1d1af0139076f347f566d860240
https://hdl.handle.net/10037/22746
https://hdl.handle.net/10037/22746